18:17 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest a PEG-based hydrogel loaded with lysostaphin could help treat orthopedic implant Staphylococcus infections. The antimicrobial enzyme lysostaphin is encapsulated in a hydrogel consisting of four-arm PEG macromers...
08:00 , Feb 15, 2016 |  BioCentury  |  Politics, Policy & Law

Nature won't wait

Biopharmaceutical companies, along with national and international research funding agencies, are launching efforts to develop vaccines against the Zika virus with no assurance that public funds will be available to purchase a successful vaccine, fuzzy...
07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

Rotavac: Phase III data

Data from the intent-to-treat (ITT) population of 6,799 infants aged 6-7 weeks at the time of enrollment in a double-blind, Indian Phase III trial showed that oral Rotavac met the primary endpoint of reducing the...
00:39 , May 15, 2013 |  BC Extra  |  Clinical News

Bharat planning Indian submission for rotavirus vaccine

Bharat Biotech International Ltd. (Hyderabad, India) said oral Rotavac significantly reduced severe rotavirus diarrhea by 56% during the first year of life vs. placebo in an Indian Phase III trial to prevent rotavirus gastroenteritis. Bharat...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Bharat Biotech, University of Maryland infectious news

Bharat and the university's Center for Vaccine Development received a $4 million award from the Wellcome Trust to develop a conjugate vaccine to prevent invasive non-typhoidal Salmonella (iNTS) infection. The partners plan to begin clinical...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Bharat Biotech infectious news

The World Health Organization (WHO) suspended the supply of Bharat's Revac B+ hepatitis B vaccine after the agency found GMP deficiencies at the company's Hyderabad plant during a September 2011 site audit. WHO said it...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

Staphylokinase: Phase III started

Bharat began an open-label, Indian Phase III trial to compare a 30 mL double-bolus of staphylokinase vs. IV streptokinase in about 120 AMI patients. Bharat has an exclusive license from ThromboGenics to develop and commercialize...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

THR-100: Phase III start

In 3Q08, Bharat will begin an Indian Phase III trial. ThromboGenics granted Bharat an exclusive license to develop and commercialize THR-100 to treat AMI in developing and certain industrialized countries (see BioCentury, Dec. 11, 2006)....
07:00 , Mar 24, 2008 |  BC Week In Review  |  Company News

Acambis, sanofi-aventis deal

Acambis and sanofi-aventis' sanofi pasteur S.A. vaccines unit added the Indian subcontinent to sanofi's rights to market and distribute Acambis' ChimeriVax-JE vaccine against Japanese encephalitis (JE). sanofi now has worldwide rights excluding the U.S., where...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Company News

Bharat Biotech sales and marketing update

Bharat Biotech International Ltd. , Hyderabad, India   Business: Infectious   Bharat Biotech launched two vaccines in India: its BioHib Haemophilus influenza type b (Hib) conjugate vaccine, and its tetravalent Comvac4-HB vaccine containing diphtheria, pertussis,...